Evidence map›Paper›PMID 37704801›Full record

ReviewInfectious diseases and therapy2023

Screening for Asymptomatic Clostridioides difficile Carriage Among Hospitalized Patients: A Narrative Review.

Mayan Gilboa, Nadav Baharav, Eyal Melzer, Gili Regev-Yochay, Dafna Yahav

Open access · goldAbstract readReview
In one paragraph

Review in Infectious diseases and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Laboratory-DetectedHealth science reports · 2026
    Article
  2. Article
  3. Risk factors for progression fromInfection control and hospital epidemiology · 2026
    Article
  4. Clostridioides difficile pathogenesis and control.Nature reviews. Microbiology · 2026
    Review
  5. A novel RNA nucleic acid amplification test more accurately distinguishes activemedRxiv : the preprint server for health sciences · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Risk Factors forAntibiotics (Basel, Switzerland) · 2025
    Article
  10. Article
  11. Pathogens (Basel, Switzerland) · 2024
    Review
  12. Toxins · 2024
    Review
  13. Pathogens (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mayan GilboaInfection Prevention Unit, Sheba Medical Center, Ramat-Gan, Israel. mayangilboa@yahoo.com.ORCID http://orcid.org/0000-0003-1754-7750
Nadav BaharavInfectious Diseases Unit, Sheba Medical Center, Ramat-Gan, Israel.
Eyal MelzerInfection Prevention Unit, Sheba Medical Center, Ramat-Gan, Israel.
Gili Regev-YochayInfection Prevention Unit, Sheba Medical Center, Ramat-Gan, Israel.
Dafna YahavFaculty of Medicine, Tel Aviv University, Ramat-Aviv, Tel-Aviv, Israel.
Tel Aviv University · ILSheba Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clostridioides difficile infection (CDI) has become the most common healthcare-associated infection in the United States, with considerable morbidity, mortality, and healthcare costs. Assessing new preventive strategies is vital. We present a literature review of studies evaluating a strategy of screening and isolation of asymptomatic carriers in hospital settings. Asymptomatic detection of C. difficile is reported in ~ 10-20% of admitted patients. Risk factors for carriage include recent hospitalization, previous antibiotics, older age, lower functional capacity, immunosuppression, and others. Asymptomatic C. difficile carriers of toxigenic strains are at higher risk for progression to CDI. They are also shedders of C. difficile spores and may contribute to the persistence and transmission of this bacterium. Screening for asymptomatic carriers at hospital admission can theoretically reduce CDI by isolating carriers to reduce transmission, and implementing antibiotic stewardship measures targeting carriers to prevent progression to clinical illness. Several observational studies, summarized in this review, have reported implementing screening and isolation strategies, and found a reduction in CDI rates. Nevertheless, the data are still limited to a few observational studies, and this strategy is not commonly practiced. Studies supporting screening were performed in North America, coinciding with the period of dominance of the 027/BI/NAP1 strain. Additional studies evaluating screening, followed by infection control and antibiotic stewardship measures, are needed.

Indexed as

Antibiotic stewardshipClostridioides difficileContact isolationInfection controlScreening

Identifiers

PMID37704801
PMCPMC10581986
OpenAlexW4386699004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.